Home/Filings/4/0000911916-17-000081
4//SEC Filing

CoLucid Pharmaceuticals, Inc. 4

Accession 0000911916-17-000081

CIK 0001348649operating

Filed

Feb 28, 7:00 PM ET

Accepted

Mar 1, 12:29 PM ET

Size

10.4 KB

Accession

0000911916-17-000081

Insider Transaction Report

Form 4
Period: 2017-03-01
Skwierczynski Raymond
Head,Pharmaceutical Operations
Transactions
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2017-03-01$40.81/sh90,000$3,672,9000 total
    Exercise: $5.69Exp: 2025-11-30Common Stock (90,000 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2017-03-01$39.75/sh15,000$596,2500 total
    Exercise: $6.75Exp: 2026-03-04Common Stock (15,000 underlying)
  • Disposition from Tender

    Common Stock

    2017-03-01$46.50/sh3,615$168,0980 total
Footnotes (4)
  • [F1]Includes 3,568 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through February 19, 2017.
  • [F2]Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest.
  • [F3]These options, which provided that 25% of the shares vested on November 30, 2016, and the remaining shares vesting in a series of 36 successive equal monthly installments upon completion of each additional month of service, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
  • [F4]These options, which provided for vesting in a series of 48 successive equal monthly installments with the first monthly installment vesting on the grant date and the future installments vesting on the first day of each calendar month, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.

Issuer

CoLucid Pharmaceuticals, Inc.

CIK 0001348649

Entity typeoperating

Related Parties

1
  • filerCIK 0001348649

Filing Metadata

Form type
4
Filed
Feb 28, 7:00 PM ET
Accepted
Mar 1, 12:29 PM ET
Size
10.4 KB